Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Arcutis ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today ...